Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

973
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
973
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertension and Postoperative Outcomes: A Retrospective Cohort Study.

Anesthesiology research and practice·2026
Same author

Mid-treatment MRI-based tumor volume reduction rate as a continuous prognostic factor after chemoradiation for cervical cancer: development and two-center internal-external validation.

Journal of radiation research·2026
Same author

Combined unilateral coronal and intraoral approach with zygomatic arch osteotomy for a dumbbell-shaped atypical lipomatous tumor of the temporal region extending into the infratemporal fossa.

Auris, nasus, larynx·2026
Same author

Adverse events in exercise interventions among older adults with frailty: a study protocol of systematic review and meta-analysis.

BMJ open·2026
Same author

Association of the Fibrosis-4 Index With Indices of Atherosclerosis in Patients With Type 2 Diabetes: An Exploratory Subanalysis of a Prospective Observational Cohort Study.

Journal of diabetes research·2026
Same author

Proton Beam Therapy Versus Photon Radiotherapy for Pediatric Neuroblastoma: A Systematic Review and Meta-Analysis (TRP-2025 Neuroblastoma).

Cancer medicine·2026

Related Experiment Video

Updated: Jun 24, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.5K

A Bayesian method to detect drug-drug interaction using external information for spontaneous reporting system.

Keisuke Tada1, Kazushi Maruo2, Masahiko Gosho2

  • 1Biostatistics & Programming, Sanofi K.K, Shinjuku-ku, Tokyo, Japan.

Statistics in Medicine
|June 6, 2024
PubMed
Summary

This study introduces a new Bayesian method to improve the detection of drug-drug interaction (DDI)-induced adverse drug reactions (ADRs) using spontaneous reporting systems. The novel approach enhances detection sensitivity, enabling earlier identification of potential safety concerns.

Keywords:
adverse drug reactiondynamic borrowingpharmacovigilancepower priorsignal detection

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.8K

Related Experiment Videos

Last Updated: Jun 24, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.5K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.8K

Area of Science:

  • Pharmacovigilance
  • Biostatistics
  • Drug Safety

Background:

  • Clinical trial safety assessments are insufficient for post-marketed drugs.
  • Adverse drug reactions (ADRs) from single drugs and drug-drug interactions (DDIs) require continuous monitoring.
  • Spontaneous reporting systems (SRS) are crucial for ongoing drug safety evaluation.

Purpose of the Study:

  • To propose a novel Bayesian method for detecting potential DDIs within SRS databases.
  • To enhance the sensitivity of DDI detection compared to existing methods.
  • To enable earlier identification of potential DDIs.

Main Methods:

  • Development of a Bayesian method utilizing a power prior for DDI detection.
  • Borrowing information from similar drugs to increase detection sensitivity.
  • Parameter tuning within the power prior to adjust information borrowing.

Main Results:

  • Simulation studies demonstrated a significant increase in detection sensitivity, up to approximately 20 points.
  • The proposed method showed potential for early detection of DDIs.
  • Analysis of a Food and Drug Administration (FDA) database supported early detection capabilities.

Conclusions:

  • The novel Bayesian method offers higher sensitivity for detecting potential DDIs.
  • A new criterion for early DDI detection is introduced.
  • The method's effectiveness relies on similar drugs exhibiting similar observed-expected ratios.